183 related articles for article (PubMed ID: 21486448)
21. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
[TBL] [Abstract][Full Text] [Related]
22. High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.
Fang C; Zhuang Y; Wang L; Fan L; Wu YJ; Zhang R; Zou ZJ; Zhang LN; Yang S; Xu W; Li JY
Cancer Sci; 2013 Aug; 104(8):996-1001. PubMed ID: 23659384
[TBL] [Abstract][Full Text] [Related]
23. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma.
Piris MA; Mollejo M; Campo E; Menárguez J; Flores T; Isaacson PG
Histopathology; 1998 Sep; 33(3):230-9. PubMed ID: 9777389
[TBL] [Abstract][Full Text] [Related]
24. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel.
Chen CC; Raikow RB; Sonmez-Alpan E; Swerdlow SH
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):1-11. PubMed ID: 10937042
[TBL] [Abstract][Full Text] [Related]
25. CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
Carulli G; Cannizzo E; Zucca A; Buda G; Orciuolo E; Marini A; Petrini M
Leuk Res; 2008 Feb; 32(2):263-7. PubMed ID: 17692374
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.
Delgado J; Matutes E; Morilla AM; Morilla RM; Owusu-Ankomah KA; Rafiq-Mohammed F; del Giudice I; Catovsky D
Am J Clin Pathol; 2003 Nov; 120(5):754-9. PubMed ID: 14608903
[TBL] [Abstract][Full Text] [Related]
27. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.
Wang L; Abbasi F; Gaigalas AK; Vogt RF; Marti GE
Cytometry B Clin Cytom; 2006 Nov; 70(6):410-5. PubMed ID: 16967494
[TBL] [Abstract][Full Text] [Related]
28. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
29. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases.
Kroft SH; Dawson DB; McKenna RW
Am J Clin Pathol; 2001 Mar; 115(3):385-95. PubMed ID: 11242795
[TBL] [Abstract][Full Text] [Related]
30. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
Almasri NM; Duque RE; Iturraspe J; Everett E; Braylan RC
Am J Hematol; 1992 Aug; 40(4):259-63. PubMed ID: 1380203
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic utility of PD-1 in B cell lymphomas.
Muenst S; Hoeller S; Willi N; Dirnhofera S; Tzankov A
Dis Markers; 2010; 29(1):47-53. PubMed ID: 20826917
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
33. CD5-expressing B-cell lymphomas/leukemias: relatively high frequency of CD5+ B-cell lymphomas with an overall poor prognosis in Nagasaki Japan.
Kamihira S; Hirakata Y; Atogami S; Sohda H; Tsuruda K; Yamada Y; Tomonaga M
Leuk Lymphoma; 1996 Jun; 22(1-2):137-42. PubMed ID: 8724541
[TBL] [Abstract][Full Text] [Related]
34. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
35. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
36. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.
Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
Hematol J; 2001; 2(5):300-6. PubMed ID: 11920265
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
[TBL] [Abstract][Full Text] [Related]
38. Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients.
Jezersek Novaković B; Benigar A
Med Oncol; 2010 Jun; 27(2):167-76. PubMed ID: 19263255
[TBL] [Abstract][Full Text] [Related]
39. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.
Borowitz MJ; Shuster J; Carroll AJ; Nash M; Look AT; Camitta B; Mahoney D; Lauer SJ; Pullen DJ
Blood; 1997 Jun; 89(11):3960-6. PubMed ID: 9166833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
